Potential "first-in-class" therapy released latest data analysis

Today, Amgen announced the latest data analysis of its potential "first-in-class" antibody therapy tezepelumab, a pivotal phase 3 clinical trial NAVIGATOR
.
The results of the analysis showed that in patients with severe asthma who had uncontrolled symptoms with nasal polyps, the addition of tezepelumab reduced the exacerbation rate by 86% compared with placebo while receiving standard treatment

Tezepelumab was jointly developed by Amgen and AstraZeneca and is a potential "first-in-class" drug that blocks the effects of thymic stromal lymphopoietin (TSLP)
.
TSLP is an epithelial cytokine that is located at the top of multiple inflammatory cascades and initiates an excessive immune response to allergies, eosinophils, and other types of airway inflammation associated with severe asthma

▲TSLP affects the immune response of a variety of immune cells (picture source: reference [2])

Pre-defined exploratory analysis showed that in severe asthma patients with nasal polyps, tezepelumab reduced the annual acute exacerbation rate (AAER) by 86% (95% CI: 70, 93); in severe asthma patients without nasal polyps Among them, this value is 52% (95% CI: 42, 61)
.

Tezepelumab improved their lung function in both groups of patients.
At week 52, the forced expiratory volume (FEV1) in one second before the bronchodilator was increased by 0.
20 liters (with nasal polyps) and 0.
13 liters (without nose).
Polyps)
.
At the same time, it also provides a clinically significant improvement for the symptoms of nasal polyps

Reference materials:

[1] New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps.

[2] Comeau & Ziegler.